DNA alkylating agent protects against spontaneous Hepatocellular carcinoma regardless of O6-methylguanine-DNA methyltransferase status

Cancer Prevention Research

Volumn 9, Issue 3, 2016, Pages 245-252

  Herzig, Maryanne C S ^a   Zavadil, Jessica A ^a   Street, Karah ^b   Hildreth, Kim ^a   Drinkwater, Norman R ^c   Reddick, Traci ^d   Herbert, Damon C ^a   Hanes, Martha A ^a   McMahan, C Alex ^a   Reddick, Robert L ^a   Walter, Christi A ^a,e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Saddleback College   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d DUKE UNIVERSITY   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; 7 METHYLGUANINE; DIETHYLNITROSAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLNITROSOUREA; ALKYLATING AGENT; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER PREVENTION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; INTESTINE CANCER; LIVER CELL CARCINOMA; LIVER PROTECTION; LUNG CANCER; LYMPH VESSEL METASTASIS; MALE; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VOLUME; ANIMAL; APOPTOSIS; C3H MOUSE; CARCINOMA, HEPATOCELLULAR; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; HUMAN; LIVER CELL; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALKYLATING AGENTS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; DIETHYLNITROSAMINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; METHYLNITROSOUREA; MICE; MICE, INBRED C3H; MICE, TRANSGENIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84962600579     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0251     Document Type: Article

References (34)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
2. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-30.
3. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a metaanalysis of cohort studies. Br J Cancer 2007;97:1005-8.
4. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 2007;12:1425-32.
5. Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? J Hepatol 2012;57:453-4.
6. Agnew LR, Gardner WU. The incidence of spontaneous hepatomas in C3H, C3H (low milk factor), and CBA mice and the effect of estrogen and androgen on the occurrence of these tumors in C3H mice. Cancer Res 1952;12:757-61.
7. Poole TM, Drinkwater NR. Strain dependent effects of sex hormones on hepatocarcinogenesis in mice. Carcinogenesis 1996;17:191-6.
8. Kemp CJ, Leary CN, Drinkwater NR. Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc Natl Acad Sci U S A 1989;86:7505-9.
9. Ramirez AG, Weiss NS, Holden AE, Suarez L, Cooper SP, Munoz E, et al. Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research. PLoS One 2012;7:e35573.
10. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
11. Drinkwater NR, Ginsler JJ. Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 1986;7:1701-7.
12. Pegg AE. Methylation of the O6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. Cancer Invest 1984;2:223-31.
13. Bilger A, Bennett LM, Carabeo RA, Chiaverotti TA, Dvorak C, Liss KM, et al. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 2004;167:859-66.
14. Gariboldi M, Manenti G, Canzian F, Falvella FS, Pierotti MA, Della Porta G, et al. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res 1993;53:209-11.
15. Manenti G, Binelli G, Gariboldi M, Canzian F, De Gregorio L, Falvella FS, et al. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics 1994;23:118-24.
16. Festing MFW. Inbred strainsinbiomedical research. New York, NY: Oxford University Press; 1979.
17. Denlinger RH, Koestner A, Wechsler W. Induction of neurogenic tumors in C3HeB-FeJ mice by nitrosourea derivatives: observations by light microscopy, tissue culture, and electron microscopy. Int J Cancer 1974;13:559-71.
18. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids 2010;2010:543531.
19. Swann PF. Why do O6-alkylguanine and O4-alkylthymine miscode? The relationship between the structure of DNA containing O6-alkylguanine and O4-alkylthymine and the mutagenic properties of these bases. Mutat Res 1990;233:81-94.
20. Zhou ZQ, Manguino D, Kewitt K, Intano GW, McMahan CA, Herbert DC, et al. Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6-methylguanine-DNA methyltransferase. Proc Natl Acad Sci U S A 2001;98:12566-71.
21. Herzig MC, Hildreth K, Huamani J, Perez M, Goins BA, McMahan CA, et al. Human O (6)-methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice. Mol Carcinog 2011;52:275-85.
22. Walter CA, Lu J, Bhakta M, Mitra S, Dunn W, Herbert DC, et al. Brain and liver targeted over expression of O6-methylguanine DNA methyltransferase in transgenic mice. Carcinogenesis 1993;14:1537-43.
23. Van Remmen H, Williams MD, Heydari AR, Takahashi R, Chung HY, Yu BP, et al. Expression of genes coding for antioxidant enzymes and heat shock proteins is altered in primary cultures of rat hepatocytes. J Cell Physiol 1996;166:453-60.
24. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
25. Moore MR, Drinkwater NR, Miller EC, Miller JA, Pitot HC. Quantitative analysis of the time-dependent development of glucose-6-phosphatasedeficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res 1981;41:1585-93.
26. Liem LK, Lim A, Li BF. Specificities of human, rat and E. Coli O6-methylguanine-DNA methyltransferases to wards the repair of O6-methyl and O6-ethylguanine in DNA. Nucleic Acids Res 1994;22:1613-9.
27. Coulter R, Blandino M, Tomlinson JM, Pauly GT, Krajewska M, Moschel RC, et al. Differences in the rate of repair of O6-alkylguanines in different sequence contexts by O6-alkylguanine-DNA alkyltransferase. Chem Res Toxicol 2007;20:1966-71.
28. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee PH, Chen CJ, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer 2003;103:440-4.
29. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6:1079-99.
30. Vesselinovitch SD, Rao KV, Mihailovich N. Neoplastic response of mouse tissues during perinatal age periods and its significance in chemical carcinogenesis. Natl Cancer Inst Monogr 1979:239-50.
31. Lu Y, Cox LA, Herbert DC, Weaker FJ, Walter CA, Adrian GS. Expression of chimeric human transferrin-chloramphenicol acetyltransferase genes in liver and brain of transgenic mice duringdevelopment. Dev Biol 1993;155:452-8.
32. Shrivastav N, Li D, Essigmann JM. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis 2010;31:59-70.
33. Claij N, van der Wal A, Dekker M, Jansen L, te Riele H. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis. Cancer Res 2003;63:2062-6.
34. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.